

## DAFTAR PUSTAKA

1. Venkatesan P. GOLD COPD report: 2023 update. *Lancet Respir Med*. 2023;11(1):18.
2. Agarwal AK, Raja A, Brown BD. Chronic Obstructive Pulmonary Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 6]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK559281/>
3. Kementerian Kesehatan Republik Indonesia. Merokok, penyebab utama Penyakit Paru Obstruktif Kronik. <https://www.kemkes.go.id/article/view/21112300001/merokok-penyebab-utama-penyakit-paru-obstruktif-kronis.html>. 2023.
4. Rahaghi FN, Pistenmaa CL. Hypercoagulation in COPD: the clot thickens. *ERJ Open Res*. 2021 Oct;7(4):00534–2021.
5. Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant Activity in Hemostasis and Thrombosis: Virchow's Triad Revisited. *Anesth Analg*. 2012 Feb;114(2):275–85.
6. Daga MK, Kumar N, Mawari G, Singh S, Mahapatra SJ, Hussain M, et al. Study of prothrombotic markers in COPD. *J Adv Res Med E-ISSN 2349-7181 P-ISSN 2394-7047*. 2020;7(4):1–6.
7. Tudor RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. *J Clin Invest*. 2012 Aug 1;122(8):2749–55.
8. MacNee W. Pathogenesis of Chronic Obstructive Pulmonary Disease. *Proc Am Thorac Soc*. 2005 Nov 1;2(4):258–66.
9. Gershon AS, Dolmage TE, Stephenson A, Jackson B. Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. *COPD J Chronic Obstr Pulm Dis*. 2012;9(3):216–26.
10. Steenland K. All-Cause and Cause-specific Death Rates by Educational Status for Two Million People in Two American Cancer Society Cohorts, 1959-1996. *Am J Epidemiol*. 2002 Jul 1;156(1):11–21.
11. Brashier BB, Kodgule R. Risk Factors and Pathophysiology of Chronic Obstructive Pulmonary Disease (COPD). 2012;60.
12. Wahyuni RD. ASPEK IMUNOLOGI CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD). 2017;4(1).
13. Page C, O'Shaughnessy B, Barnes P. Pathogenesis of COPD and asthma. *Pharmacol Ther Asthma COPD*. 2017;1–21.
14. Agustí A, Hogg JC. Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. Drazen JM, editor. *N Engl J Med*. 2019 Sep 26;381(13):1248–56.

15. Perhimpunan Dokter Paru Indonesia. PPOK (Penyakit Paru Obstruktif Kronik). Diagnosis dan Penatalaksanaan. Jakarta: Perhimpunan Dokter Paru Indonesia; 2016. 1–78 p.
16. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2015;(2).
17. Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. *Pharmacol Ther*. 2019 Jun;198:160–88.
18. Kyriakopoulos C, Gogali A, Kostikas K, Konstantinidis A. Hypercoagulable State in COPD-A Comprehensive Literature Review. *Diagnostics*. 2021 Aug 10;11(8):1447.
19. Ashorobi D, Ameer MA, Fernandez R. Thrombosis. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 6]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK538430/>
20. Liu M, Hu R, Jiang X, Mei X. Coagulation dysfunction in patients with AECOPD and its relation to infection and hypercapnia. *J Clin Lab Anal* [Internet]. 2021 Apr [cited 2023 May 2];35(4). Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jcla.23733>
21. Mejza F, Lamprecht B, Niżankowska-Mogilnicka E, Undas A. Arterial and Venous Thromboembolism in Chronic Obstructive Pulmonary Disease: From Pathogenic Mechanisms to Prevention and Treatment. *Adv Respir Med*. 2015 Nov 10;83(6):485–94.
22. Fimognari FL, Scarlata S, Conte ME, Incalzi RA. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2008;3(1):89–96.
23. Brassington K, Selemidis S, Bozinovski S, Vlahos R. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. *Clin Sci*. 2019 Apr 15;133(7):885–904.
24. Malerba M, Clini E, Malagola M, Avanzi GC. Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. *Expert Rev Hematol*. 2013 Aug;6(4):475–83.
25. Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. *Eur Respir J*. 2003 Nov 2;22(Supplement 46):28s–32s.
26. Børvik T, Brækkan SK, Enga K, Schirmer H, Brodin EE, Melbye H, et al. COPD and risk of venous thromboembolism and mortality in a general population. *Eur Respir J*. 2016 Feb;47(2):473–81.
27. Aleva FE, Voets LW, Simons SO, de Mast Q, van der Ven AJ, Heijdra YF. Prevalence and localization of pulmonary embolism in unexplained acute

- exacerbations of COPD: a systematic review and meta-analysis. *Chest*. 2017;151(3):544–54.
28. Wedzicha JA, Hurst JR. Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism. *Thorax*. 2007 Feb 1;62(2):103–4.
  29. Abd Elsalam HM, Mohamed MA, El Gammal MS, El-Shabrawy M. Hypercoagulability in different respiratory diseases. *Egypt J Chest Dis Tuberc*. 2013 Apr;62(2):331–41.
  30. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. *Blood*. 2003 May 15;101(10):3765–77.
  31. Lemichez E, Lecuit M, Nassif X, Bourdoulous S. Breaking the wall: targeting of the endothelium by pathogenic bacteria. *Nat Rev Microbiol*. 2010 Feb;8(2):93–104.
  32. Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinness C, Deans A, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. *Thorax*. 2011 Sep 1;66(9):769–74.
  33. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. *Eur Respir J*. 2007 May 1;29(5):923–9.
  34. Ogawa S, Gerlach H, Esposito C, Pasagian-Macaulay A, Brett J, Stern D. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. *J Clin Invest*. 1990 Apr 1;85(4):1090–8.
  35. Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. *Thorax*. 1991 Jul 1;46(7):504–7.
  36. McDonald T, Cottrell M, Clift R. Effects of short-term hypoxia on platelet counts of mice. *Blood*. 1978 Jan 1;51(1):165–75.
  37. Drost EM. Oxidative stress and airway inflammation in severe exacerbations of COPD. *Thorax*. 2005 Apr 1;60(4):293–300.
  38. Bernardo I, Bozinovski S, Vlahos R. Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities. *Pharmacol Ther*. 2015 Nov;155:60–79.
  39. Rahman I. Oxidative stress and redox regulation of lung inflammation in COPD. *Eur Respir J*. 2006 Jul 1;28(1):219–42.
  40. Kovačič APM, Caprnda M, Mrhar A, Kubatka P, Locatelli I, Zolakova B, et al. Impact of drugs on venous thromboembolism risk in surgical patients. *Eur J Clin Pharmacol*. 2019 Jun;75(6):751–67.

41. Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. *J Thromb Haemost*. 2006 Sep;4(9):1914–8.
42. Hou H, Ge Z, Ying P, Dai J, Shi D, Xu Z, et al. Biomarkers of deep venous thrombosis. *J Thromb Thrombolysis*. 2012 Oct;34(3):335–46.
43. Anghel L, Sascău R, Radu R, Stătescu C. From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis. *Int J Mol Sci*. 2020 Mar 11;21(6):1920.
44. Wang J, Ding Y. Prevalence and risk factors of pulmonary embolism in acute exacerbation of chronic obstructive pulmonary disease and its impact on outcomes: a systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci*. 2021;25(6):2604–16.
45. Lankeit M, Held M. Incidence of venous thromboembolism in COPD: linking inflammation and thrombosis? *Eur Respir J*. 2016 Feb;47(2):369–73.
46. Silva DR, Coelho AC, Gazzana MB, Menna Barreto SS, Knorst MM. D-dimer Levels in Stable COPD Patients: A Case-control Study. *COPD J Chronic Obstr Pulm Dis*. 2012 Jul 26;9(4):426–31.
47. Johnson ED, Schell JC, Rodgers GM. The D-dimer assay. *Am J Hematol*. 2019;94(7):833–9.
48. Yang R, Moosavi L. Prothrombin Time. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 6]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK544269/>
49. Sun W, Cao Z, Ma Y, Wang J, Zhang L, Luo Z. Fibrinogen, a Promising Marker to Evaluate Severity and Prognosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Observational Study. *Int J Chron Obstruct Pulmon Dis*. 2022;1299–310.
50. Rountree KM, Yaker Z, Lopez PP. Partial Thromboplastin Time. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 6]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK507772/>
51. Shikdar S, Vashisht R, Bhattacharya PT. International Normalized Ratio (INR). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 May 15]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK507707/>
52. Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *The Lancet*. 2018 Apr;391(10131):1706–17.
53. Ho T, Cusack RP, Chaudhary N, Satia I, Kurmi OP. Under- and over-diagnosis of COPD: a global perspective. *Breathe*. 2019 Mar;15(1):24–35.

54. Perez TA, Castillo EG, Ancochea J, Pastor Sanz MT, Almagro P, Martínez-Cambor P, et al. Sex differences between women and men with COPD: A new analysis of the 3CIA study. *Respir Med.* 2020 Sep;171:106105.
55. Maselli DJ, Bhatt SP, Anzueto A, Bowler RP, DeMeo DL, Diaz AA, et al. Clinical Epidemiology of COPD. *Chest.* 2019 Aug;156(2):228–38.
56. De Matteis S, Jarvis D, Darnton A, Hutchings S, Sadhra S, Fishwick D, et al. The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort. *Eur Respir J.* 2019 Jul;54(1):1900186.
57. Lytras T, Kogevinas M, Kromhout H, Carsin AE, Antó JM, Bentouhami H, et al. Occupational exposures and 20-year incidence of COPD: the European Community Respiratory Health Survey. *Thorax.* 2018 Nov;73(11):1008–15.
58. Garg A, Kaur M, Jindal V. COPD Patient with a Classical Radiological Sign. *Adv Respir Med.* 2021 Dec 29;89(6):606–7.
59. Iqbal MS, Al-Saikhan FI, Ahmed NJ, Iqbal MZ. Pharmacoeconomic Analysis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *J Pharm Res Int.* 2020 Apr 12;59–66.
60. Raad S, Smith C, Allen K. Nutrition status and chronic obstructive pulmonary disease: can we move beyond the body mass index? *Nutr Clin Pract.* 2019;34(3):330–9.
61. Ji Z, De Miguel-Díez J, Castro-Riera CR, Bellón-Cano JM, Gallo-González V, Girón-Matute WI, et al. Differences in the Outcome of Patients with COPD according to Body Mass Index. *J Clin Med.* 2020 Mar 5;9(3):710.
62. Muzlifa R, Mulyadi M, Husnah H. The relation of Brinkman index and body mass index with spirometry result of chronic obstructive pulmonary disease (COPD) outpatients in the pulmonology and respiratory medicine department of Zainoel Abidin general hospital. *World Nutr J.* 2022;5(2):1–7.
63. Hasni D, Warlem N. The Degree of Smoking for Out Patient with COPD in Padang. In 2019.
64. Ruvuna L, Sood A. Epidemiology of Chronic Obstructive Pulmonary Disease. *Clin Chest Med.* 2020 Sep;41(3):315–27.
65. Zhou B, Liu S, He D, Wang K, Wang Y, Yang T, et al. Fibrinogen is a promising biomarker for chronic obstructive pulmonary disease: evidence from a meta-analysis. *Biosci Rep.* 2020 Jul 31;40(7):BSR20193542.
66. Kim TH, Oh DK, Oh YM, Lee SW, Lee SD, Lee JS. Fibrinogen as a potential biomarker for clinical phenotype in patients with chronic obstructive pulmonary disease. *J Thorac Dis.* 2018 Sep;10(9):5260–8.
67. Gyawali B, Ramakrishna K, Dharmoon AS. Sepsis: The evolution in definition, pathophysiology, and management. *SAGE Open Med.* 2019;7:2050312119835043.

68. Celli BR, Anderson JA, Brook R, Calverley P, Cowans NJ, Crim C, et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. *BMJ Open Respir Res.* 2019 May;6(1):e000431.
69. Chen L, Xu W, Chen J, Zhang H, Huang X, Ma L, et al. Evaluating the clinical role of fibrinogen, D-dimer, mean platelet volume in patients with acute exacerbation of COPD. *Heart Lung.* 2023;57:54–8.
70. Swathini CS, Chowdary M. Plasma Levels of Fetuin B and Fibrinogen in Chronic Obstructive Pulmonary Disease: A Preliminary Cross-sectional Study. *J Clin Diagn Res.* 2021;15(9).
71. Van Bragt JJMH, Vijverberg SJH, Weersink EJM, Richards LB, Neerincx AH, Sterk PJ, et al. Blood biomarkers in chronic airways diseases and their role in diagnosis and management. *Expert Rev Respir Med.* 2018 May 4;12(5):361–74.
72. Gonçalves I, Guimarães M, Van Zeller M, Menezes F, Moita J, Simão P. Clinical and molecular markers in COPD. *Pulmonology.* 2018;24(4):250–9.
73. Karsdal M. Biochemistry of collagens, laminins and elastin: structure, function and biomarkers. Academic Press; 2019.
74. Akwe J, Fair N, Fongeh T. Overview of epidemiology, pathophysiology, diagnosis and staging with 2020 Updates. *Med Res Arch.* 2020;8(2).
75. Kyomoto Y, Kanazawa H, Tochino Y, Watanabe T, Asai K, Kawaguchi T. Possible role of airway microvascular permeability on airway obstruction in patients with chronic obstructive pulmonary disease. *Respir Med.* 2019;146:137–41.
76. Moon JY, Leitao Filho FS, Shahangian K, Takiguchi H, Sin DD. Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD). *Expert Rev Proteomics.* 2018 Nov 2;15(11):923–35.
77. Hlapčić I, Belamarić D, Bosnar M, Kifer D, Vukić Dugac A, Rumora L. Combination of Systemic Inflammatory Biomarkers in Assessment of Chronic Obstructive Pulmonary Disease: Diagnostic Performance and Identification of Networks and Clusters. *Diagnostics.* 2020 Nov 30;10(12):1029.
78. Mohan M, Parthasarathi A, S K C, Biligere Siddaiah J, Mahesh PA. Fibrinogen: A Feasible Biomarker in Identifying the Severity and Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Cureus [Internet].* 2021 Aug 3 [cited 2023 May 2]; Available from: <https://www.cureus.com/articles/64301-fibrinogen-a-feasible-biomarker-in-identifying-the-severity-and-acute-exacerbation-of-chronic-obstructive-pulmonary-disease>
79. Zhang Q, Yue Y, Zheng R. Clusterin as a serum biomarker candidate contributes to the lung fibroblasts activation in chronic obstructive pulmonary disease. *Chin Med J (Engl).* 2022;135(09):1076–86.
80. Pieters M, Wolberg AS. Fibrinogen and fibrin: An illustrated review. *Res Pract Thromb Haemost.* 2019;3(2):161–72.

81. Masood A, Amin M, Qasim F, H. Sharfi M. Study of Levels of Plasma Fibrinogen and its Association with Disease Severity in Patients with Chronic Obstructive Pulmonary Disease. *Pak J Med Health Sci.* 2021 Nov 30;15(11):3403–5.
82. Göbel K, Eichler S, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG. The coagulation factors fibrinogen, thrombin, and factor XII in inflammatory disorders—a systematic review. *Front Immunol.* 2018;9:1731.
83. Ehsan K, Zulfiqar S, Hassan A, Waseem H. Plasma Fibrinogen as a Biomarker of Stable and Exacerbated Chronic Obstructive Pulmonary Disease. *Open Biomark J.* 2021;11(1).
84. Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. *Am J Respir Crit Care Med.* 2019 May 15;199(10):1195–204.
85. Dicker D, Nguyen G, Abate D, Abate KH, Abay SM, Abbafati C, et al. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet.* 2018 Nov;392(10159):1684–735.
86. Mallah H, Ball S, Sekhon J, Parmar K, Nugent K. Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy. *Respir Med.* 2020 Sep;171:106098.
87. Aydın C, Yıldız BP, Hattatoğlu DG. D-dimer/Fibrinogen ratio and recurrent exacerbations might have a potential impact to predict 90-day mortality in patients with COPD exacerbation. *Malawi Med J.* 2021 Dec 22;33(4):276–80.
88. Saymaz ZT, Çelik D, Yıldız M, Ertan Ö. The effects of D-dimer high rates on prognosis and mortality in chronic obstructive respiratory disease. *Anatol Curr Med J.* 2022 Jan 24;4(1):44–50.
89. Uysal P. Evaluation of relationship between disease severity, mean platelet volume, and platelet distribution width in stable chronic obstructive pulmonary disease. *Arch Clin Exp Med.* 2018 Nov 30;3(3):132–7.
90. Somborac-Bačura A, Rumora L, Žanić Grubišić T, Rako I, Rogić D, Vukić Dugac A, et al. Platelet indices in stable chronic obstructive pulmonary disease – association with inflammatory markers, comorbidities and therapy. *Biochem Medica.* 2020 Feb 15;30(1):60–73.
91. Koç Ç, Şahin F. What Are the Most Effective Factors in Determining Future Exacerbations, Morbidity Weight, and Mortality in Patients with COPD Attack? *Medicina (Mex).* 2022 Jan 21;58(2):163.
92. Çaltekin İ, Gökçen E, Albayrak L, Atik D, Savrun A, Kuşdoğan M, et al. Inflammatory Markers And Blood Gas Analysis In Determining The Severity Of Chronic Obstructive Pulmonary Disease. 2020;
93. Zinellu A, Zinellu E, Mangoni AA, Pau MC, Carru C, Pirina P, et al. Clinical significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte

ratio in acute exacerbations of COPD: present and future. *Eur Respir Rev.* 2022 Dec 31;31(166):220095.

94. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. *J Intensive Care.* 2020 Dec;8(1):49.
95. Ilyas M. Association of Fibrinogen and Neutrophil Levels with Incidence and Severity of Chronic Obstructive Pulmonary Disease. *Int J Sci.* 2019;48(1).